Skip to main content

Next-Generation Oncolytic Vaccinia Vectors

Part of the Methods in Molecular Biology book series (MIMB,volume 797)


Oncolytic vaccinia viruses have made some impressive advances over the last 5 years, with a range of ­different backbones displaying significant antitumor responses in preclinical models, and some exciting clinical results being reported against liver cancers. Because the virus is capable of rapid spread within the tumor, has evolved to spread relatively undetected within the blood stream, does not integrate into the host cell chromosome, and can infect almost any cell type, it is well-suited to the requirements for a successful oncolytic. In addition, the extensive clinical use of this virus means that contraindications to its use are known, and approved and experimental antivirals are available. Furthermore, because the virus has a large array of virulence genes whose deletion may target different properties of the cancer cell, and a large cloning capacity allowing for insertion of multiple transgenes, the possibilities for further development of novel and next-generation oncolytic vectors are multitude.

Key words

  • Vaccinia
  • Oncolytic virus
  • Virotherapy
  • Tumor targeting
  • Replication selective

This is a preview of subscription content, access via your institution.

Buying options

USD   49.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-61779-340-0_14
  • Chapter length: 11 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
USD   109.00
Price excludes VAT (USA)
  • ISBN: 978-1-61779-340-0
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   149.00
Price excludes VAT (USA)
Hardcover Book
USD   149.99
Price excludes VAT (USA)
Fig. 1.

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more


  1. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. 1997 Vaccinia virus immune evasion. Immunol Rev;159:137–54.

    CAS  CrossRef  Google Scholar 

  2. Buller RM, Palumbo GJ. 1991 Poxvirus pathogenesis. Microbiol Rev;55:80–122.

    CAS  CrossRef  Google Scholar 

  3. Thorne SH, Hwang TH, Kirn DH. 2005 Vaccinia virus and oncolytic virotherapy of cancer. Curr Opin Mol Ther;7:359–65.

    PubMed  Google Scholar 

  4. Thorne SH, Kirn DH. 2004 Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus. Expert Opin Biol Ther;4:1307–21.

    CAS  CrossRef  Google Scholar 

  5. Chakrabarti S, Sisler JR, Moss B. 1997 Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques;23:1094–7.

    CAS  CrossRef  Google Scholar 

  6. Coupar BE, Oke PG, Andrew ME. 2000 Insertion sites for recombinant vaccinia virus construction: effects on expression of a foreign protein. J Gen Virol;81:431–9.

    CAS  CrossRef  Google Scholar 

  7. Zhao H, Doyle TC, Coquoz O, Kalish F, Rice BW, Contag CH. 2005 Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. J Biomed Opt;10:41210.

    CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Steve H. Thorne .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Thorne, S.H. (2012). Next-Generation Oncolytic Vaccinia Vectors. In: Kirn, D., Liu, TC., Thorne, S. (eds) Oncolytic Viruses. Methods in Molecular Biology, vol 797. Humana, Totowa, NJ.

Download citation

  • DOI:

  • Published:

  • Publisher Name: Humana, Totowa, NJ

  • Print ISBN: 978-1-61779-339-4

  • Online ISBN: 978-1-61779-340-0

  • eBook Packages: Springer Protocols